ADAPTGEN PHARMACEUTICAL

Adaptgen Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and immunology. The company leverages a proprietary structure-based drug design platform to target complex biological pathways, aiming to create best-in-class and first-in-class treatments. Its lead candidate, AP-101, is a dual TLR7/8 agonist currently being evaluated in clinical trials for the treatment of advanced solid tumors. Additionally, the company is advancing AP-201, a highly selective TYK2 inhibitor, for various autoimmune and inflammatory indications. Adaptgen's pipeline also includes several pre-clinical programs targeting HPK1 and USP7 to address unmet needs in cancer immunotherapy.